Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
about
Dynamic and influential interaction of cancer cells with normal epithelial cells in 3D culture.Spontaneous epithelial-mesenchymal transition and resistance to HER-2-targeted therapies in HER-2-positive luminal breast cancer.HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance.Differential expression of HIF-1α in CD44+CD24-/low breast ductal carcinomasCytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.Metformin: multi-faceted protection against cancer.Phenolic secoiridoids in extra virgin olive oil impede fibrogenic and oncogenic epithelial-to-mesenchymal transition: extra virgin olive oil as a source of novel antiaging phytochemicals.Special suppressive role of miR-29b in HER2-positive breast cancer cells by targeting Stat3.Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin).Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells.Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties.Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancerAutophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancerPPARγ maintains ERBB2-positive breast cancer stem cells.STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.Overcoming challenges of ovarian cancer stem cells: novel therapeutic approaches.Proteomic analysis reveals that CD147/EMMPRIN confers chemoresistance in cancer stem cell-like cells.Stem cell property epithelial-to-mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in KRAS wild-type tumor cells.
P2860
Q30596963-35E78AC0-4443-481B-B6F0-3E6987DD09DAQ31132069-93482FED-CCB2-4C4B-A2D3-036D19CD1373Q33737278-82D85DE5-3060-4C70-80F3-01FCFD0C54F8Q35206212-F2D1877C-17FC-4276-9A5A-062EB75F9F5AQ35740160-9A3859A5-0797-4730-8BD6-EFAAC17A36FDQ35764409-E77C1586-0206-4BBD-AD47-A9198A0BEAD9Q35770306-3023B448-FC9E-40AE-8575-0D6B85D5125BQ35826465-067954ED-2020-478F-B56E-FD0C8070617BQ36050677-8D802D69-EAFD-4D11-A09A-6DFAC3B85AE7Q36426509-F6ADBEC3-D7DF-43CA-9B38-00DB9C32D397Q36544839-DFDB3C65-2B84-4560-B062-7FB60711AE6DQ36618624-552A614A-F207-4553-ACD1-5172AEDD887FQ36695069-CAD75465-269C-4265-B047-372B1DA600DDQ36781090-6149FC02-7DB9-43A4-9E1C-EDC727CEFD8EQ36898399-345236F0-BC13-4AB0-8C25-AB77B7198726Q36926125-385AA6E7-3E96-445F-BAEE-72D3ACCB8F32Q37111104-5EB2C8A6-92CF-4556-B1DB-506EBB03A552Q37501777-0DF53790-2D0C-4054-9518-1BDB2F3A0973Q37504298-05065CC6-FB19-411F-989A-344746EA37BEQ37666730-F5E1A63D-842F-4B30-938B-6F41F6D747DBQ37978771-9202273F-3257-4ACB-BBA4-C0334C354564Q39171812-80D275F5-9748-4FD5-9418-83CE61863036Q39628198-78F4B9D3-4828-40FB-BE0B-D92019A69749
P2860
Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Dynamic emergence of the mesenchymal CD44
@nl
Dynamic emergence of the mesen ...... ce to trastuzumab (Herceptin).
@en
type
label
Dynamic emergence of the mesenchymal CD44
@nl
Dynamic emergence of the mesen ...... ce to trastuzumab (Herceptin).
@en
prefLabel
Dynamic emergence of the mesenchymal CD44
@nl
Dynamic emergence of the mesen ...... ce to trastuzumab (Herceptin).
@en
P2093
P50
P1476
Dynamic emergence of the mesen ...... ce to trastuzumab (Herceptin).
@en
P2093
Alejandro Vazquez-Martin
Cristina Oliveras-Ferraros
Eugeni Lopez-Bonet
Silvia Cufí
Sonia Del Barco
P356
10.1016/J.BBRC.2010.05.041
P407
P577
2010-05-12T00:00:00Z